SCH 50911

Drug Profile

SCH 50911

Latest Information Update: 17 Sep 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Schering-Plough
  • Class Antidementias; Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action GABA B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Absence epilepsy; Cognition disorders

Most Recent Events

  • 15 Jun 2004 Discontinued - Preclinical for Absence seizures in USA (unspecified route)
  • 15 Jun 2004 Discontinued for Cognition disorders in USA (unspecified route)
  • 25 Aug 1998 No-Development-Reported for Absence seizures in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top